All currency values in $ millions unless otherwise noted
| Income Statement | DEC 2025 | DEC 2024 | DEC 2023 |
|---|---|---|---|
| Revenues | |||
| Revenue | $0 | $0 | – |
| Cost of Revenue | $0 | – | – |
| Gross Profit | $0 | – | – |
| General & Administrative | $7 | $3 | $3 |
| Research & Development | $2 | $0 | $1 |
| Total Operating Expenses | $9 | $3 | $4 |
| Operating Income | -$9 | -$3 | -$4 |
| Non-Operating | |||
| Net Interest Expense | -$0 | -$0 | -$0 |
| Other Non-Operating Income (Expense) | $0 | $1 | -$1 |
| Net Income | |||
| Net Income | -$9 | -$2 | -$5 |
| Per Share Data | |||
| Revenue Per Share | $0.05 | $0.00 | – |
| EPS (Basic) | -$18.75 | -$6.00 | -$13.50 |
| EPS (Diluted) | -$18.75 | -$6.00 | -$13.50 |
| Weighted Avg Shares (Basic) | 34.6M | 28.8M | 26.4M |
| Weighted Avg Shares (Diluted) | 34.6M | 28.8M | 26.4M |
| Shares Outstanding | 461,714.507 | 383,773.933 | 352,068.12 |
Jupiter Neurosciences (JUNS) financials: revenue, profit and margins
Jupiter Neurosciences (JUNS) generated about n/a in revenue and -$9 million in net income (a -39,662.8% net margin) over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Jupiter Neurosciences profitable?+
Jupiter Neurosciences reported about -$9 million in net loss over the trailing twelve months, a net margin of roughly -39,662.8%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Jupiter Neurosciences's profit margins?+
Jupiter Neurosciences runs a gross margin of about 80.6%, an operating margin of about -40,873.2%, a net margin of about -39,662.8%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
SourceFinancial statements computed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 19 Sept 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with JUNS
Spot a number that looks wrong? Check it in JUNS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing JUNS
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.